(Reuters) – Vitae Pharmaceuticals Inc said its drug to treat type 2 diabetes in overweight patients did not meet its main goal in a mid-stage study testing it as an add-on therapy. The drug, being co-developed with German drugmaker Boehringer Ingelheim, was tested as an add-on therapy to metformin, a commonly prescribed diabetes drug. The blood sugar levels of patients taking the drug as an add-on therapy did not reduce significantly, Vitae said in a statement on Monday.